Introduction Grifols, a Spanish multinational company, has emerged as a significant player in the global healthcare landscape, specialising in the development and manufacture of plasma-derived medicines. Founded in 1909, the company has significantly influenced biotechnology, especially in providing critical therapies for patients with rare, chronic conditions. Understanding Grifols is crucial as the demand for innovative